Evidence map›Paper›PMID 21990301›Full record

ArticleJAMA2011

Celiac disease diagnosis and management: a 46-year-old woman with anemia.

Daniel Leffler

Abstract readCase ReportsClinical Conference
In one paragraph

Article in JAMA, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Celiac Disease: Diagnostic Standards and Dilemmas.Diseases (Basel, Switzerland) · 2015
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Vitamin D status and concomitant autoimmunity in celiac disease.Journal of clinical gastroenterology · 2013
    Article
  13. Review
  14. Quality improvement in gastroenterology clinical practice.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Daniel LefflerDepartment of Gastroenterology, Beth Israel Deaconess Medical Center, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, USA. dleffler@caregroup.harvard.edu

Funding

Non-invasive markers of celiac disease activity during gluten challengeK23DK082619 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI LEFFLER, DANIEL ALEXANDER · 2009 to 2013
$887k
Validation of Peripheral Microparticles as Novel Biomarkers of Celiac Disease ActR03DK095937 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI LEFFLER, DANIEL ALEXANDER · 2013 to 2014
$174k
NIDDK NIH HHS K23 DK082619NIDDK NIH HHS R03 DK095937
6 · The paper itself

Abstract

Celiac disease is one of the most prevalent autoimmune gastrointestinal disorders, but as the case of Ms J illustrates, diagnosis is often delayed or missed. Based on serologic studies, the prevalence of celiac disease in many populations is estimated to be approximately 1% and has been increasing steadily over the last 50 years. Evaluation for celiac disease is generally straightforward and uses commonly available serologic tests; however, the signs and symptoms of celiac disease are nonspecific and highly heterogeneous, making diagnosis difficult. Although celiac disease is often considered a mild disorder treatable with simple dietary changes, in reality celiac disease imparts considerable risks, including reduced bone mineral density, impaired quality of life, and increased overall mortality. In addition, a gluten-free diet is highly burdensome and can profoundly affect patients and their families. For these reasons, care of individuals with celiac disease requires prompt diagnosis and ongoing multidisciplinary management.

Indexed as

Diet, Gluten-FreeAutoantibodiesCeliac DiseaseFemaleHumansImmunoglobulin AMiddle AgedRiskTransglutaminasesAutoantibodiesImmunoglobulin ATransglutaminases

Identifiers

PMID21990301
PMCPMC3373262

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.